Pharmafile Logo

rovalpituzumab tesirine

- PMLiVE

Regeneron’s Libtayo approved as flexible dosing schedule in EU

The flexible dosing schedule has been approved for patients with skin, lung and cervical cancer

- PMLiVE

Nuformix proposes acquisition of Biovara

The companies focus on fibrosis and oncology, and novel treatments for respiratory conditions, respectively

- PMLiVE

AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences

The new site will expand research capabilities across immunology, neuroscience and oncology

- PMLiVE

AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

- PMLiVE

AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics

This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments

- PMLiVE

Smarter science, sharper strategy: Expert insights from ASCO® 2026

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Inizio

- PMLiVE

AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer

The results from a global phase 3 trial show the longest survival data ever reported in this setting

Doctor speaking to patient

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

Cuttsy + Cuttsy

- PMLiVE

AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo

Rinvoq is the first and only systemic medication approved in the EU for NSV

- PMLiVE

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...

Inizio

- PMLiVE

AbbVie to acquire Apogee Therapeutics in $10.9bn deal

The acquisition includes clinical-stage candidates for atopic dermatitis and asthma

- PMLiVE

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

Inizio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links